NCT07082270 2026-04-15Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple MyelomaRoswell Park Cancer InstitutePhase 1 Withdrawn
NCT06400264 2024-05-06Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)National Cancer Institute (NCI)Phase 2 Withdrawn